Alternative therapies for Clostridium difficile infections

Pharmacotherapy

Volumn 30, Issue 12, 2010, Pages 1266-1278

  Venuto, Charles ^a,b   Butler, Mary ^b   Dodds Ashley, Elizabeth ^b   Brown, Jack ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; Evidence based medicine; Gastroenterology; Infectious disease; Outcomes

Indexed keywords

ANTIINFECTIVE AGENT; FIDAXOMICIN; FRUCTOSE OLIGOSACCHARIDE; FUSIDIC ACID; METRONIDAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CDA1; MONOCLONAL ANTIBODY CDB1; NITAZOXANIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INFECTION RATE; LACTOBACILLUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; MORBIDITY; MORTALITY; NEUROTOXICITY; NONHUMAN; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; PREBIOTICS; PROBIOTICS;

EID: 78650188067     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.12.1266     Document Type: Review

References (76)

1. Owens RC. Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs 2007;67:487-502.
2. Kuijper EJ, van Dissel JT, Wilcox MH. Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 2007;20:376-83.
3. Hall IC, O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe: Bacillus difficilis. Am J Dis Child 1935;48:390-402.
4. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81:5-9.
5. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(S6):2-18.
6. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561-7.
7. Wilcox MH. Gastrointestinal disorders and the critically ill: Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 2003;17:475-93.
8. Barbut F, Lalande V, Burghoffer B, Thien HV, Grimprel E, Petit JC. Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol 2002;40:2079-83. (Pubitemid 34596388)
9. Komatsu M, Kato H, Aihara M, et al. High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 2003;22:525-9.
10. Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
11. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93.
12. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
13. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
14. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:1043-6.
15. Pham PA, Bartlett JG. HIV guide: vancomycin. Johns Hopkins Poc-It Center [PDA software]. Baltimore, MD: Johns Hopkins Medicine, 2009.
16. Pham PA, Bartlett JG. ABX guide: metronidazole. Johns Hopkins Poc-It Center [PDA software]. Baltimore, MD: Johns Hopkins Medicine, 2009.
17. Husni R, Hachem R, Hanna H, Raad I. Risk factors for vancomycin-resistant Enterococcus infection in colonized patients with cancer. Infect Control Hosp Epidemiol 2002;23:102-3.
18. Shin JW, Yong D, Kim MS, et al. Sudden increase in vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother 2003;9:62-7. (Pubitemid 36504373)
19. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donesky CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403-6.
20. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624-31.
21. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from U.S. short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-15.
22. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk: four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-5.
23. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
24. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
25. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005;173:1037-42.
26. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
27. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
28. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
29. Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med 2008;359:1932-40.
30. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283-90.
31. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33. (Pubitemid 27096783)
32. Joyce AM, Burns DL. Recurrent Clostridium difficile colitis. Compr Ther 2004;30:160-3.
33. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double-blind placebo-controlled trial [online exclusive article]. BMJ 2007;335:80. Available from http://dx.doi.org/10.1136/bmj.39231.599815.55. (Erratum in BMJ 2007; Available from http://dx.doi.org/10.1136/bmj.39283.393067. AD.)
34. Ruszczynski M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Ailment Pharmacol Ther 2008;28:154-61. (Pubitemid 351782820)
35. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Ailment Pharmacol Ther 2005;21:583-90.
36. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7:59-62.
37. Lewis S, Burmeister S, Cohen S, Brazier J, Awasthi A. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Ailment Pharmacol Ther 2005;21:469-77.
38. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of colonic bacteria. J Apply Bacteriol 1994;77:412-20. (Pubitemid 24316912)
39. Trejo FM, Minnaard J, Perez PF, De Antoni GL. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Anaerobe 2006;12:186-93. (Pubitemid 44331635)
40. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:223-8.
41. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinic Infect Dis 2006;43:421-7. (Pubitemid 44157148)
42. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-6.
43. DeLalla F, Privitera G, Rinaldi E, Ortisi G, Santoro D, Rizzardini G. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992;36:2192-6.
44. Swedish CDAD Study Group. Treatment of Clostridium difficile-associated diarrhea and colitis with an oral preparation of teicoplanin; a dose-finding study. Scand J Infect Dis 1994;26:309-16.
45. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-18. (Pubitemid 26255600)
46. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004;54:211-16.
47. Noren T, Wullt M, Akerlund T, Back E, Odenholt I, Burman LG. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 2006;50:3028-32.
48. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547-52.
49. Louie TJ, Pepper J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411-20.
50. Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40:1173-80.
51. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987;9:155-9.
52. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365-7. (Pubitemid 37038627)
53. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-17.
54. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fail conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10.
55. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
56. Graul T, Cain AM, Karpa KD. Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality. Med Hypotheses 2009;73:194-8.
57. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580-5.
58. Hopkins MJ, Sharp R, Macfarlane GT. Variation in human intestinal microbiota with age. Dig Liver Dis 2002;34(suppl 2):S12-18.
59. Fredenucci I, Chomarat M, Boucaud C, Flandrois JP. S. boulardii fungemia in a patient receiving ultra-levuretherapy. Clin Infect Dis 1998;27:222-3.
60. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41:5340-3.
61. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80.
62. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004;38:62-9.
63. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS 2006;17:280-2.
64. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009;33(suppl 1):S46-50.
65. Villano SA, Tatarowicz W, Seiberling M, Gerding DN, Gomez A, Monnot-Chase E. Phase 1 evaluation of an oral suspension of VP 20621, spores of a non-toxigenic C. difficile strain, in healthy older subjects pretreated with oral vancomycin. Presented at the 50th interscience conference on antimicrobial agents and chemotherapy, Boston, MA, September 12-15, 2010.
66. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis [online exclusive article]. BMJ 2002;324:1361. Available from www.bmj.com/content/324/7350/1361.full.
67. Cornely OA, Miller M, Louie T, Crook D, Sears P, Gorbach SL. Randomized controlled trial of fidaxomicin versus vancomycin in treatment of recurrent Clostridium difficile infection. Presented at the 50th interscience conference on antimicrobial agents and chemotherapy, Boston, MA, September 12-15, 2010.
68. Johnson S, Schriever C, Galang M. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8.
69. Garey KW, Jiang ZD, Bellard AMT, DuPont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009;43:91-2.
70. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48:1732-5.
71. Gustafsson A, Berstad A, Lund-Tonnesen S, Midtvedt T, Norin E. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhea. Scand J Gastroenterol 1999;34:580-6.
72. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1989;1:1156-60.
73. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000;95:3283-5.
74. Faust G, Langelier D, Haddad H, Menard DB. Treatment of recurrent pseudomembranous colitis with stool transplantation: report of six cases [abstract]. Can J Gastroenterol 2002;16:A43.
75. You DM, Franzos MA, Holman RP. Successful treatment of fulminate Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med 2008;148:632-3.
76. van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill 2009;14:article 4.